CORBEVAX A Promising Weapon in the Fight Against COVID-19
Amidst the tumultuous and formidable COVID-19 pandemic, humanity finds itself grappling with an extraordinary and mind-boggling challenge of unprecedented proportions. This virus has mercilessly claimed countless lives while sending economies into a tailspin of chaos. A stark contrast emerges when we consider the vaccination divide, with approximately 77% of individuals in high- and upper-middle-income countries having received at least one vaccine dose, whereas a mere 10% of those in low-income countries have had access to such protection. Wealthy countries are providing booster doses and even a fourth dose, while many people around the world do not have access to the first and second doses. the advent of the CORBEVAX vaccine will help close this vaccination gap.
The Birth of CORBEVAX
CORBEVAX is a protein subunit vaccine, it was developed using recombinant protein technology that has been used to produce recombinant hepatitis B vaccines around the world, including in countries such as India, China, Indonesia, Brazil and Bangladesh. CORBEVAX is the name of a vaccine produced by the Indian company Biological E using a formulation from the Texas team, and is significantly cheaper than the already affluent national standard mRNA vaccine at a significantly lower cost compared to the mRNA vaccine: the cost per dose to the Indian government is around US$2.
The CORBEVAX vaccine underwent development by harnessing the spike protein-the very mechanism employed by the virus to infiltrate human cells-as its primary antigenic component. Moreover, to augment its immunostimulatory properties, the vaccine incorporates Dynavax's CpG 1018, a potent adjuvant that fortifies the immune response and propels the vaccine's effectiveness to unprecedented heights. The vaccine received the approval of the esteemed Drug Controller General of India (DCGI) on 28 December 2021.
How CORBEVAX Wages War Against COVID-19
All COVID-19 vaccines serve the fundamental purpose of instructing the immune system to identify the virus and prepare the body for an impending assault. CORBEVAX is a proven approach to immunization that stimulates an immune response by directly delivering fragments of the virus that the vaccine is designed to protect against. The teams of Dr Bottazzi and Dr Hotez used yeast to "brew" the coronavirus' "spike" protein. The coronavirus uses the "spike" protein to infiltrate healthy human cells to replicate and further attack the human body.
The CORBEVAX vaccine teaches the body to recognize this "spike" protein so that it is better prepared when an actual virus invades. Novavax uses a similar technology, but mRNA vaccines like those from Pfizer and Moderna teach the body to make the coronavirus' "spike" protein on its own.
A Vaccine Built for the World
The production cost of mRNA vaccines on the market is generally high, and the manufacturing process is also relatively complicated. In addition, storage and transportation require ultra-low temperature environments. In contrast, the original intention of the development of the CORBEVAX vaccine is to hope that countries all over the world will be vaccinated against the new crown vaccine, using relatively mature protein manufacturing technology with a history of more than 40 years to develop a low-cost, easy-to-produce and transport vaccine. Not only can it be produced on a large scale in various countries, but the storage temperature can be reached by ordinary refrigerators. All these advantages show that it is expected to increase the popularity of the new crown vaccine in low- and middle-developed countries. At present, CORBEVAX has been confirmed by large-scale clinical trials in the United States to be safe and tolerable, and has 90% effectiveness in preventing new coronary pneumonia infection.
.
